Cargando…
Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP)
The Medicines Patent Pool (MPP) was established in 2010 to ensure timely access to low-cost generic versions of patented antiretroviral (ARV) medicines in low- and middle-income countries (LMICs) through the negotiation of voluntary licences with patent holders. While robust data on the savings gene...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444652/ https://www.ncbi.nlm.nih.gov/pubmed/28542239 http://dx.doi.org/10.1371/journal.pone.0177770 |
_version_ | 1783238737623252992 |
---|---|
author | Juneja, Sandeep Gupta, Aastha Moon, Suerie Resch, Stephen |
author_facet | Juneja, Sandeep Gupta, Aastha Moon, Suerie Resch, Stephen |
author_sort | Juneja, Sandeep |
collection | PubMed |
description | The Medicines Patent Pool (MPP) was established in 2010 to ensure timely access to low-cost generic versions of patented antiretroviral (ARV) medicines in low- and middle-income countries (LMICs) through the negotiation of voluntary licences with patent holders. While robust data on the savings generated by MPP and other major global public health initiatives is important, it is also difficult to quantify. In this study, we estimate the savings generated by licences negotiated by the MPP for ARV medicines to treat HIV/AIDS in LMICs for the period 2010–2028 and generate a cost-benefit ratio–based on people living with HIV (PLHIVs) in any new countries which gain access to an ARV due to MPP licences and the price differential between originator’s tiered price and generics price, within the period where that ARV is patented. We found that the direct savings generated by the MPP are estimated to be USD 2.3 billion (net present value) by 2028, representing an estimated cost-benefit ratio of 1:43, which means for every USD 1 spent on MPP, the global public health community saves USD 43. The saving of USD 2.3 billion is equivalent to more than 24 million PLHIV receiving first-line ART in LMICs for 1 year at average prices today. |
format | Online Article Text |
id | pubmed-5444652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-54446522017-06-12 Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP) Juneja, Sandeep Gupta, Aastha Moon, Suerie Resch, Stephen PLoS One Research Article The Medicines Patent Pool (MPP) was established in 2010 to ensure timely access to low-cost generic versions of patented antiretroviral (ARV) medicines in low- and middle-income countries (LMICs) through the negotiation of voluntary licences with patent holders. While robust data on the savings generated by MPP and other major global public health initiatives is important, it is also difficult to quantify. In this study, we estimate the savings generated by licences negotiated by the MPP for ARV medicines to treat HIV/AIDS in LMICs for the period 2010–2028 and generate a cost-benefit ratio–based on people living with HIV (PLHIVs) in any new countries which gain access to an ARV due to MPP licences and the price differential between originator’s tiered price and generics price, within the period where that ARV is patented. We found that the direct savings generated by the MPP are estimated to be USD 2.3 billion (net present value) by 2028, representing an estimated cost-benefit ratio of 1:43, which means for every USD 1 spent on MPP, the global public health community saves USD 43. The saving of USD 2.3 billion is equivalent to more than 24 million PLHIV receiving first-line ART in LMICs for 1 year at average prices today. Public Library of Science 2017-05-25 /pmc/articles/PMC5444652/ /pubmed/28542239 http://dx.doi.org/10.1371/journal.pone.0177770 Text en © 2017 Juneja et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Juneja, Sandeep Gupta, Aastha Moon, Suerie Resch, Stephen Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP) |
title | Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP) |
title_full | Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP) |
title_fullStr | Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP) |
title_full_unstemmed | Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP) |
title_short | Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP) |
title_sort | projected savings through public health voluntary licences of hiv drugs negotiated by the medicines patent pool (mpp) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444652/ https://www.ncbi.nlm.nih.gov/pubmed/28542239 http://dx.doi.org/10.1371/journal.pone.0177770 |
work_keys_str_mv | AT junejasandeep projectedsavingsthroughpublichealthvoluntarylicencesofhivdrugsnegotiatedbythemedicinespatentpoolmpp AT guptaaastha projectedsavingsthroughpublichealthvoluntarylicencesofhivdrugsnegotiatedbythemedicinespatentpoolmpp AT moonsuerie projectedsavingsthroughpublichealthvoluntarylicencesofhivdrugsnegotiatedbythemedicinespatentpoolmpp AT reschstephen projectedsavingsthroughpublichealthvoluntarylicencesofhivdrugsnegotiatedbythemedicinespatentpoolmpp |